First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort

被引：6

作者：

Galvin, Angeline ^{[1
,23
]}

Courtinard, Coralie ^{[1
,2
]}

Bouteiller, Fanny ^{[3
]}

Gourgou, Sophie ^{[4
,5
]}

Dalenc, Florence ^{[6
]}

Jacot, William ^{[7
]}

Arnedos, Monica ^{[8
]}

Bailleux, Caroline ^{[9
]}

Dieras, Veronique ^{[10
]}

Petit, Thierry ^{[11
]}

Emile, George ^{[12
]}

Dubray-Longeras, Pascale ^{[13
]}

Frenel, Jean-Sebastien ^{[14
]}

Bachelot, Thomas ^{[15
]}

Mailliez, Audrey ^{[16
]}

Brain, Etienne ^{[17
]}

Desmoulins, Isabelle ^{[18
]}

Massard, Vincent ^{[19
]}

Patsouris, Anne ^{[20
]}

Goncalves, Anthony ^{[21
]}

Grinda, Thomas ^{[22
]}

Delaloge, Suzette ^{[22
]}

Bellera, Carine ^{[1
,3
]}

机构：

[1] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, Epicene Team, Inserm,UMR 1219, F-33000 Bordeaux, France

[2] Unicancer, Data & Partnership Dept, 101 Rue Tolbiac, F-75654 Paris, France

[3] Inserm, Inst Bergonie, Clin & Epidemiol Res Unit, Comprehens Canc Ctr,CIC1401, F-33000 Bordeaux, France

[4] Inst Canc Montpellier, Biometr Unit, 208 Rue Apothicaires, F-34298 Montpellier, France

[5] Univ Montpellier, F-34000 Montpellier, France

[6] Oncopole Claudius Regaud IUCT, Dept Med Oncol, 1 Ave Irene Joliot Curie, F-31059 Toulouse, France

[7] Inst Canc Montpellier, Dept Med Oncol, 208 Rue Apothicaires, F-34298 Montpellier, France

[8] Inst Bergonie, Dept Med Oncol, 229 Cours Argonne, F-33000 Bordeaux, France

[9] Ctr Antoine Lacassagne, Dept Med Oncol, 33 Ave Valambrose, F-06189 Nice, France

[10] Ctr Eugene Marquis, Dept Med Oncol, Ave Bataille Flandres Dunkerque, F-35000 Rennes, France

[11] Ctr Paul Strauss, Dept Med Oncol, 3 Rue Porte Hop, F-67000 Strasbourg, France

[12] Ctr Francois Baclesse, Dept Med Oncol, 3 Ave Gen Harris, F-14000 Caen, France

[13] Ctr Jean Perrin, Dept Med Oncol, 58 Rue Montalembert, F-63011 Clermont Ferrand, France

[14] Inst Cancerol Lorraine, Dept Med Oncol, Blvd Jacques Monod, F-44805 Nantes, France

[15] Ctr Leon Berard, Dept Med Oncol, 28 Prom Lea & Napoleon Bullukian, F-69008 Lyon, France

[16] Ctr Oscar Lambret, Med Oncol Dept, 3 Rue Freder Combemale, F-59000 Lille, France

[17] Inst Curie, Dept Med Oncol, 26 Rue Ulm, F-75005 Paris, France

[18] Ctr Georges Francois Leclerc, Dept Med Oncol, F-21079 Dijon, France

[19] Inst Cancerol Lorraine, Med Oncol Dept, 6 Ave Bourgogne, F-54519 Vandoeuvre Les Nancy, France

[20] Inst Cancerol Ouest Paul Papin, Dept Med Oncol, 15 Rue Andre Boquel, F-49055 Angers, France

[21] Inst Paoli Calmettes, Dept Med Oncol, 232 Blvd Sainte Marguer, F-13009 Marseille, France

[22] Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94800 Villejuif, France

[23] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, Team EPICENE, Inserm,UMR 121, 146 Rue Leo Saignat, F-33000 Bordeaux, France

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 196卷

关键词：

Real-word data; Metastatic breast cancer; Survival endpoints; IMPACT; AGE; GUIDELINES; DIAGNOSIS; THERAPY;

D O I：

10.1016/j.ejca.2023.113422

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To describe first-line treatment patterns, overall survival (OS) and real-world progression-free survival (rwPFS) in young women (<40) with metastatic breast cancer (mBC), as compared to women aged 40-69. Materials and Methods: Data on adult women diagnosed with mBC (2008-2017) were extracted from the ESME mBC database (NCT03275311) which includes consecutive patients starting first-line metastatic treatment in one of the 18 French Comprehensive cancer centers. We reported first-line therapeutic strategy and prognostic factors of OS and rwPFS for women aged < 40 and 40-69. Results: In total, 14,897 mBC women were included (1512 aged <40). HR+ /HER2- mBC was the most frequent subtype. First-line treatment differed between young patients and older ones for HR+ /HER2- and Triple Negative (TN) mBC. Median OS for women aged < 40 and 40-69, respectively, was 46.9 and 46.2 months for HR+ /HER2- mBC; 13.5 and 15.2 for TN mBC; and, 60.7 and 55.1 for HER2 + mBC. Median rwPFS under first line treatment was 11.6 and 11.9 months for HR+ /HER2- in women aged < 40 and 40-69, respectively; 5.5 and 5.9 for TN, and, 13.3 and 12.9 for HER2 + . Factors associated with shorter OS and rwPFS were similar for both women aged < 40 and 40-69 and included >= 3 metastatic sites, visceral metastases, and longer MFI, with timevarying effects observed for several prognostic factors. Conclusion: Young women presented more frequently with TN and HER2 + subtypes and aggressive mBC than women aged 40-69 did. Prognostic factors of OS and rwPFS were quite similar between age groups and mBC subtypes.

引用

页数：10

共 50 条

[11] Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Gobbini, Elisa
Ezzalfani, Monia
Dieras, Veronique
Bachelot, Thomas
Brain, Etienne
Debled, Marc
Jacot, William
Mouret-Reynier, Marie Ange
Goncalves, Anthony
Dalenc, Florence
Patsouris, Anne
Ferrero, Jean Marc
Levy, Christelle
Lorgis, Veronique
Vanlemmens, Laurence
Lefeuvre-Plesse, Claudia
Mathoulin-Pelissier, Simone
Petit, Thierry
Uwer, Lionel
Jouannaud, Christelle
Leheurteur, Marianne
Lacroix-Triki, Magali
Cleaud, Audrey Lardy
Robain, Mathieu
Courtinard, Coralie
Cailliot, Christian
Perol, David
Delaloge, Suzette
EUROPEAN JOURNAL OF CANCER, 2018, 96 : 17 - 24
[12] Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
Thomas Grinda
Natacha Joyon
Amélie Lusque
Sarah Lefèvre
Laurent Arnould
Frédérique Penault-Llorca
Gaëtan Macgrogan
Isabelle Treilleux
Anne Vincent-Salomon
Juliette Haudebourg
Aurélie Maran-Gonzalez
Emmanuelle Charafe-Jauffret
Coralie Courtinard
Camille Franchet
Véronique Verriele
Etienne Brain
Patrick Tas
Cécile Blanc-Fournier
Agnès Leroux
Delphine Loussouarn
Anca Berghian
Eva Brabencova
Jean Pierre Ghnassia
Jean-Yves Scoazec
Suzette Delaloge
Thomas Filleron
Magali Lacroix-Triki
npj Breast Cancer, 7
[13] IMPACT OF AGE AT DIAGNOSIS OF METASTATIC BREAST CANCER ON OVERALL SURVIVAL IN THE REAL-LIFE ESME MBC COHORT
Frank, Sophie
Tchokothe, Corinne
Carton, Matthieu
Mouret-Fourme, Emmanuelle
Dubot, Coraline
Campone, Mario
Pistilli, Barbara
Dalenc, Florence
Mailliez, Audrey
Levy, Christelle
Jacot, William
Marc, Debled U.
Leheurteur, Marianne
Lefeuvre, Claudia
Goncalves, Anthony
Uwer, Lionel
Ferrero, Jean -Marc
Eymard, Jean-Christophe
Petit, Thierry
Mouret-Reynier, Marie-Ange
Guesmia, Tahar
Bachelot, Thomas
Robain, Mathieu
Cottu, Paul
BREAST, 2018, 41 : S16 - S16
[14] Metastatic inflammatory breast cancer: Clinical features and outcomes in the national, multicentric, real-life ESME cohort
Monneur, A.
Bertucci, F.
Lardy-Cleaud, A.
Augereau, P.
Debled, M.
Levy, C.
Mouret-Reynier, M. A.
Coudert, B.
Mailliez, A.
Bachelot, T.
Ferrero, J-M
Guiu, S.
Uwer, L.
Campone, M.
Cottu, P.
Jouannaud, C.
Rouge, T. De la Motte
Leheurteur, M.
Petit, T.
Pistilli, B.
Dalenc, F.
Simon, G.
Robain, M.
Viens, P.
Lerebours, F.
Goncalves, A.
CANCER RESEARCH, 2019, 79 (04)
[15] First-line systemic treatment outcomes in a real-world advanced pancreatic cancer cohort
Tafenzi, H. A.
Takniouine, Y. Ait
Haag, E. K.
Abdillahi, B. D.
Choulli, F.
Baladi, A.
Essadi, I.
Belbaraka, R.
ANNALS OF ONCOLOGY, 2024, 35 : S153 - S153
[16] First-line treatment in older patients with metastatic colorectal cancer: A large real-world study
Basile, D.
Bergamo, F.
Ongaro, E.
Cinausero, M.
Conca, V.
Ambrosini, M.
Lucchetti, J.
Rosati, G.
Avallone, A.
Di Paolo, G.
Lai, E.
Lutrino, E. S.
Di Nardo, P.
Zurlo, I. V.
Cortese, C.
Carullo, M.
Leo, S.
Di Donato, S.
Pietrantonio, F.
Aprile, G.
ANNALS OF ONCOLOGY, 2024, 35 : S447 - S447
[17] Real-world first-line treatment patterns and outcomes in hormone-receptor positive advanced breast cancer patients: A multicenter, retrospective study
Chen, Z.
Wang, X.
Ouyang, Q.
Tian, C.
Wang, Y.
Wang, H.
Wang, J.
Liang, H.
Wang, C.
Wu, X.
Zhang, Y.
Zhang, P.
Ren, D.
Huang, J.
Zheng, Y.
Cao, W.
Shao, X.
ANNALS OF ONCOLOGY, 2021, 32 : S465 - S466
[18] Real-life management and prognosis of young women (≤ 40 yo) with de novo metastatic breast cancer in the multicenter national observational ESME program
Francois, A.
Lusque, A.
Levy, C.
Pistilli, B.
Brain, E.
Pasquier, D.
Debled, M.
Thery, J. C.
Goncalves, A.
Desmoulins, I.
Rouge, T. de la Motte
Faure, C.
Ferrero, J-M.
Eymard, J-C.
Reynier, M. A. Mouret
Petit, T.
Payen, O.
Uwer, L.
Guiu, S.
Frenel, J-S.
ANNALS OF ONCOLOGY, 2020, 31 : S365 - S365
[19] Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
Sandhya Mehta
Jipan Xie
Raluca Ionescu-Ittu
Xiaoyu Nie
Winghan J. Kwong
Oncology and Therapy, 2023, 11 : 481 - 493
[20] Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+?Metastatic Breast Cancer
Mehta, Sandhya
Xie, Jipan
Ionescu-Ittu, Raluca
Nie, Xiaoyu
Kwong, Winghan J.
ONCOLOGY AND THERAPY, 2023, 11 (04) : 481 - 493

← 1 2 3 4 5 →